Mounjaro at SOBOBA Medical Weight Loss Clinics

New Patients Offer | Mounjaro Injections | First Shot Only $39 | Then $98 Per Shot
Free Doctor Visits | No Startup Fees | No Contracts

A new medication is available, offering us an exciting option for weight loss and diabetes control. Mounjaro (generic name: tirzepatide) is a dual-action medication that acts on both GLP-1 and GIP receptors (mimicking hormones we naturally produce in the gut) to produce a reduced appetite, earlier fullness, and improved blood sugar regulation

WHAT DOES THE DATA SHOW ABOUT MOUNJARO FOR WEIGHT LOSS?

For people struggling with obesity without diabetes, the SURMOUNT-1 trial showed that the highest dose of Mounjaro produced an impressive 20.9% weight loss in 72 weeks, or an average of 52 pounds lost! In addition, more than one-third of participants on the highest dose lost over 25% of their body weight, a weight loss range that approaches that seen after bariatric surgery and not previously observed with other anti-obesity medications. For comparison, the placebo-controlled group lost an average of only 3.1% with diet and lifestyle changes alone over the same time frame. While it is difficult to compare results across studies, prior studies have shown that the next most impressive medication, Wegovy (generic: semaglutide), produces an average weight loss of 14.9% over a slightly shorter time frame.

Additional benefits in overall health were seen in this study as well. Over 95% of participants with prediabetes at the start of the study achieved normal blood sugar levels by the end of the study, compared with around 62% achieved by the placebo group with diet and exercise alone. There were also significant improvements in cholesterol levels, blood pressure, and overall reported physical function for those on Mounjaro compared to the placebo. For people with Type 2 Diabetes, the SURPASS-1 trial showed that the highest dose of Mounjaro produced an average weight loss of 11% (about 25 pounds) and an average a1c reduction of 2.3% over a 40-week period! While not a perfect comparison, prior studies on the highest dose of Wegovy (generic: semaglutide) showed an average 9.6% weight loss and a 1.6% reduction in A1c over 68 weeks in people with diabetes.

At the completion of your diet, when you have reached your goal weight, you will be given instructions to follow so you do not regain the weight you have lost. The results of Mounjaro injections will last as long as you follow the instructions.

Mounjaro is a prescription injectable medication used along with diet and exercise to improve blood sugar in people with type 2 diabetes. On the official product site, it is described as a once-weekly non-insulin injection, and current U.S. information also states it is approved for adults and children age 10 and older with type 2 diabetes.

Mounjaro is not a vitamin booster or general wellness shot. It is a prescription medication containing tirzepatide and is intended to be prescribed and monitored medically rather than offered as a casual add-on service.

Mounjaro is taken once weekly by subcutaneous injection. The official dosing materials describe a 2.5 mg starting dose for 4 weeks, followed by escalation to higher doses as appropriate and tolerated.

Not usually. Lilly’s dosing guidance says the 2.5 mg dose is for treatment initiation and is not intended for glycemic control. After the starting period, the dose is typically increased based on the patient’s response and tolerability.

People often ask about Mounjaro because medications in this category can affect appetite, metabolic regulation, and glucose control. Even so, whether it is appropriate for someone depends on a medical evaluation, their diagnosis, and the provider’s treatment plan. This is an inference based on Mounjaro’s approved role in glycemic control and its prescription-only status.

According to the prescribing information, Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

The official prescribing information highlights important risks and precautions including thyroid C-cell tumor warning language, pancreatitis, hypoglycemia when used with certain other diabetes medications, hypersensitivity reactions, and acute kidney injury related to volume depletion.

A proper consultation should review your medical history, current medications, diabetes status, treatment goals, and any contraindications or risk factors before prescribing. That approach follows from the medication’s prescription status, boxed warning, and dosing requirements.

Yes. Mounjaro is designed as an ongoing once-weekly treatment used together with diet and exercise, with dosing adjusted over time as needed. Continued follow-up is important to monitor response, tolerability, and dose progression.

Disclaimer: Results may vary from person to person. This website does not provide medical advice.These statements have not been evaluated by the Food and Drug Administration. SOBOBA Medical Weight loss program is not intended to diagnose, treat, cure or prevent any disease.